During the early phase (first 6 months, from day 30 to day 210), GLP-1 RA Users demonstrated a lower risk of all-cause death (HR 0.484, 95% CI 0.470–0.498) but a higher risk of the composite outcome (HR 1.216, 95% CI 1.126–1.313), acute pancreatitis (HR 1.143, 95% CI 1.055–1.239), and pancreatic cancer (HR 1.170, 95% CI 1.010–1.357), compared to Non–GLP-1 RA Users. This evidence concerns the gene GLP1R and pancreatic neoplasm.